Johnson & Johnson Sells Off Ahead of Earnings: Time to Cut Losses or Double Down?

  • 📰 Investingcom
  • ⏱ Reading Time:
  • 43 sec. here
  • 4 min. at publisher
  • 📊 Quality Score:
  • News: 27%
  • Publisher: 53%

Johnson & Johnson Noticias

Netflix Inc,ABIOMED Inc

Stocks Analysis by Investing.com (Damian Nowiszewski) covering: Johnson & Johnson, Netflix Inc, ABIOMED Inc. Read Investing.com (Damian Nowiszewski)'s latest article on Investing.com

Despite bullish markets, Johnson & Johnson's stock price has declined over 4% year-to-date.Investors eagerly anticipate next week's earnings for insights into Johnson & Johnson's performance.

Investor attention is now turning to the upcoming quarterly results, set to be published next Tuesday. These results present an opportunity for Johnson & Johnson stock to reverse the downtrend, provided the number exceeds forecasts.This company specializes in therapies to break down calcification in arteries, reducing the risk of heart attacks.

If the final readings match forecasts, it will mean a decrease from last year's figures, when earnings per share stood at $2.68 and revenues reached $24.746 billion. This negative outlook contributes to the ongoing selling pressure on the stock.The downward trend that started last month continues, with a high probability of dipping below the $150 per share mark. If sellers succeed in this move, the primary scenario is to target last year's lows of around $145 per share.

 

Gracias por tu comentario. Tu comentario será publicado después de ser revisado.
Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:

 /  🏆 450. in MX

México Últimas Noticias, México Titulares